Q-omics provides the consensus-scored MIR5590 profile across patient tissues and cancer cell-line models. MIR5590 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, MIR5590 is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, MIR5590 RNA expression shows 6,521 significant gene co-expression associations, with the highest sampling consensus in PRAD. Together, these results highlight STAD, KIRC, and PRAD as cancer lineages where MIR5590 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR5590 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR5590 survival associations across molecular data types. MIR5590 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR5590 RNA expression–survival associations across cancer types. High MIR5590 expression shows unfavorable associations in STAD, CHOL, SARC, ESCA and THCA, but favorable associations in KIRC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for MIR5590 RNA expression.
This table summarizes MIR5590 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR5590. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR5590 shows lower tumor expression in THCA and higher tumor expression in KIRC. The KIRC box plot shows higher MIR5590 RNA expression in tumor versus normal tissue (log2 FC = +0.212, t-test p = .021).
This table shows molecular features associated with MIR5590 in patient tissues and cancer cell lines. In patient samples, MIR5590 shows the broadest associations at the RNA and protein expression levels, with PRAD recurring as the lineage with the largest associated feature set.
